company background image
XERS logo

Xeris Biopharma Holdings NasdaqGS:XERS Stock Report

Last Price

US$2.22

Market Cap

US$329.1m

7D

-5.9%

1Y

-18.1%

Updated

13 Jun, 2024

Data

Company Financials +

Xeris Biopharma Holdings, Inc.

NasdaqGS:XERS Stock Report

Market Cap: US$329.1m

Xeris Biopharma Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xeris Biopharma Holdings
Historical stock prices
Current Share PriceUS$2.22
52 Week HighUS$3.26
52 Week LowUS$1.46
Beta1.31
1 Month Change16.84%
3 Month Change-0.45%
1 Year Change-18.08%
3 Year Changen/a
5 Year Changen/a
Change since IPO-5.93%

Recent News & Updates

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Jun 04
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Recent updates

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Jun 04
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 30

Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Mar 09
Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Mar 06
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Jan 05
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Aug 09

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Aug 01

Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven

May 21

Xeris Continues To Execute And Build Long-Term Value Potential

Feb 22

Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition

Dec 20

Shareholder Returns

XERSUS PharmaceuticalsUS Market
7D-5.9%1.5%1.2%
1Y-18.1%17.5%20.5%

Return vs Industry: XERS underperformed the US Pharmaceuticals industry which returned 18.2% over the past year.

Return vs Market: XERS underperformed the US Market which returned 21.8% over the past year.

Price Volatility

Is XERS's price volatile compared to industry and market?
XERS volatility
XERS Average Weekly Movement8.1%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: XERS's share price has been volatile over the past 3 months.

Volatility Over Time: XERS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005377Paul Edickwww.xerispharma.com

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.

Xeris Biopharma Holdings, Inc. Fundamentals Summary

How do Xeris Biopharma Holdings's earnings and revenue compare to its market cap?
XERS fundamental statistics
Market capUS$329.13m
Earnings (TTM)-US$64.40m
Revenue (TTM)US$171.36m

1.9x

P/S Ratio

-5.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XERS income statement (TTM)
RevenueUS$171.36m
Cost of RevenueUS$29.30m
Gross ProfitUS$142.06m
Other ExpensesUS$206.46m
Earnings-US$64.40m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.43
Gross Margin82.90%
Net Profit Margin-37.58%
Debt/Equity Ratio-2,502.4%

How did XERS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.